These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 25226617

  • 1. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 2. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
    Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.
    J Natl Cancer Inst; 2013 Mar 20; 105(6):405-23. PubMed ID: 23446755
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
    Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL.
    Blood; 2006 Jun 01; 107(11):4532-9. PubMed ID: 16469872
    [Abstract] [Full Text] [Related]

  • 4. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
    Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.
    J Hematol Oncol; 2014 Apr 28; 7():37. PubMed ID: 24775308
    [Abstract] [Full Text] [Related]

  • 5. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
    Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R, Holyoake TL.
    Blood; 2014 Aug 28; 124(9):1492-501. PubMed ID: 24957147
    [Abstract] [Full Text] [Related]

  • 6. Suppression of autophagy by BCR/ABL.
    Calabretta B, Salomoni P.
    Front Biosci (Schol Ed); 2012 Jan 01; 4(2):453-60. PubMed ID: 22202070
    [Abstract] [Full Text] [Related]

  • 7. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.
    Blood; 2008 Mar 01; 111(5):2843-53. PubMed ID: 18156496
    [Abstract] [Full Text] [Related]

  • 8. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG, Holyoake TL.
    Biochem Soc Trans; 2007 Nov 01; 35(Pt 5):1347-51. PubMed ID: 17956348
    [Abstract] [Full Text] [Related]

  • 9. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.
    Cancer Res; 2008 Dec 01; 68(23):9624-33. PubMed ID: 19047139
    [Abstract] [Full Text] [Related]

  • 10. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.
    Blood; 2012 Mar 08; 119(10):2335-45. PubMed ID: 22262776
    [Abstract] [Full Text] [Related]

  • 11. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 12. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.
    Blood; 2012 Feb 09; 119(6):1501-10. PubMed ID: 22184410
    [Abstract] [Full Text] [Related]

  • 13. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 09; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 14. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gérard D, Lee JY, Mazumder A, Ahamed M, Christov C, Kim DW, Dicato M, Bormans G, Han BW, Diederich M.
    Clin Epigenetics; 2020 May 19; 12(1):69. PubMed ID: 32430012
    [Abstract] [Full Text] [Related]

  • 15. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J.
    J Clin Invest; 2016 Oct 03; 126(10):3961-3980. PubMed ID: 27643437
    [Abstract] [Full Text] [Related]

  • 16. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.
    J Clin Invest; 2013 Oct 03; 123(10):4144-57. PubMed ID: 23999433
    [Abstract] [Full Text] [Related]

  • 17. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Leukemia; 2017 Oct 03; 31(10):2065-2074. PubMed ID: 28321124
    [Abstract] [Full Text] [Related]

  • 18. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.
    Leuk Res; 2008 Jun 03; 32(6):962-71. PubMed ID: 18190961
    [Abstract] [Full Text] [Related]

  • 19. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
    Li Y, Hu J, Song H, Wu T.
    Biochem Biophys Res Commun; 2018 Nov 02; 505(3):858-864. PubMed ID: 30301525
    [Abstract] [Full Text] [Related]

  • 20. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE, Sheng G, Li XJ, Turhan A, Jiang X.
    J Exp Med; 2008 Oct 27; 205(11):2657-71. PubMed ID: 18936234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.